pemetrexed + erlotinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer
Conditions
Non-Small-Cell Lung Cancer
Trial Timeline
Nov 1, 2007 → Jan 1, 2012
NCT ID
NCT00550173About pemetrexed + erlotinib
pemetrexed + erlotinib is a phase 2 stage product being developed by Eli Lilly for Non-Small-Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00550173. Target conditions include Non-Small-Cell Lung Cancer.
What happened to similar drugs?
7 of 20 similar drugs in Non-Small-Cell Lung Cancer were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00550173 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer